NasdaqGM:RANIPharmaceuticals
Why Rani Therapeutics (RANI) Is Up 23.6% After Promising Oral Semaglutide Preclinical Data Release
Rani Therapeutics Holdings announced it would present preclinical data on its RaniPill® oral delivery platform at ObesityWeek® 2025, highlighting that oral semaglutide (RT-116) in dogs is bioequivalent to subcutaneous injections and produces similar weight loss.
This research could generate interest, as it demonstrates the potential for the RaniPill to enable oral delivery of peptide drugs traditionally administered via injection.
We'll examine how these promising preclinical results for...